A metabolic amplification strategy for spherical nucleic acid immunogenicity driven by simvastatin-CpG codelivery

Area of Science:

• Nanotechnology
• Immunotherapy
• Drug Delivery

Background:

• Spherical nucleic acids (SNAs) show potential in immunotherapy but have limited innate immune activation.
• Enhancing immune activation is crucial for improving the therapeutic efficacy of SNAs.

Purpose of the Study:

• To develop an improved SNA platform for immunotherapy by integrating a metabolic modulator with CpG.
• To investigate the mechanism of enhanced immune activation and evaluate the therapeutic potential of the engineered system.

Main Methods:

• Engineered simvastatin-CpG SNAs (S-SNAs) by integrating simvastatin, a metabolic modulator, with CpG oligonucleotides.
• Investigated the in vitro effects of S-SNAs on macrophage activation and CpG-induced signaling pathways, focusing on the mevalonate pathway.
• Assessed in vivo cellular uptake, humoral immune responses (RBD-specific), and antitumor activity in a murine melanoma model.

Main Results:

• Simvastatin potentiates CpG-induced innate immune signaling, leading to regulated macrophage activation in vitro.
• S-SNAs demonstrated improved cellular uptake and enhanced RBD-specific humoral immune responses compared to controls.
• In a murine melanoma model, S-SNAs exhibited significant antitumor activity and prolonged survival without systemic toxicity.

Conclusions:

• Metabolic modulation via simvastatin is an effective strategy to enhance the immunological performance of nucleic acid-based nanostructures.
• The S-SNAs system represents a promising platform for immunotherapy with enhanced efficacy and safety.
• This study highlights the potential of combining metabolic modulators with nanostructures for advanced therapeutic applications.